文献速递神经胸部CT

COVID-19 卒中肺尖检查研究:疑似急性卒中患者中的诊断与预后影像生物标志物

COVID-19 Stroke Apical Lung Examination Study: A Diagnostic and Prognostic Imaging Biomarker in Suspected Acute Stroke.
PubMed 文献 · AJNR Am J Neuroradiol · 2020-09-17

这项多中心回顾性研究纳入225例疑似急性卒中患者的颈动脉CTA,评估肺尖磨玻璃影作为COVID-19诊断与预后影像标志物的价值。肺尖磨玻璃影出现率为22.2%,与逆转录聚合酶链反应相比敏感度75%、特异度81%,多因素分析OR=11.65;该征象还是30天死亡率升高的独立预测因子(18.0% vs 5.7%,HR=3.51)。

要点

  • 疑似急性卒中患者行颈动脉CTA时,应观察包含在扫描范围内的肺尖有无磨玻璃影。
  • 肺尖磨玻璃影诊断COVID-19的敏感度75%、特异度81%,观察者间可靠性高(Fleiss κ=0.81)。
  • 肺尖磨玻璃影是30天死亡率升高的独立预测因子(18.0% vs 5.7%,HR=3.51)。

核心结论

  • 颈动脉CTA肺尖有无磨玻璃影是一项简单、可靠且准确的COVID-19诊断与预后影像生物标志物。
  • 该发现对疑似卒中患者的早期COVID-19识别及后续限制疾病传播具有重要临床意义。

研究设计与样本

  • 多中心回顾性研究,纳入225例疑似急性卒中患者,来自3个超急性卒中单元(2020年3月至4月)。
  • 评估颈动脉CTA上候选诊断影像生物标志物的可靠性与准确性,以逆转录聚合酶链反应为参照。
  • 采用单因素和多因素统计分析人口学、临床特征及COVID-19和卒中危险因素。

关键影像表现/征象

  • 肺尖磨玻璃影见于22.2%(50/225)的患者。
  • 肺尖磨玻璃影具有高观察者间可靠性(Fleiss κ=0.81;95%CI 0.68-0.95)。
  • 同期可获取的其他人口学、临床及CTA影像特征均不能诊断COVID-19。

诊断标准与关键数值

  • 以逆转录聚合酶链反应为参照,肺尖磨玻璃影诊断COVID-19的敏感度为75%(95%CI 56-87),特异度为81%(95%CI 71-88)。
  • 多因素分析中肺尖磨玻璃影与COVID-19的OR=11.65(95%CI 4.14-32.78),P<.001。
  • 肺尖磨玻璃影预测30天死亡率:18.0% vs 5.7%,P=.017;HR=3.51(95%CI 1.42-8.66),P=.006。

临床应用与阅片要点

  • 阅读疑似急性卒中患者的颈动脉CTA时,应常规观察肺尖有无磨玻璃影,以早期识别可能的COVID-19。
  • 肺尖磨玻璃影的出现或缺失可作为报告中的诊断与预后信息,有助于限制疾病传播。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND AND PURPOSE: Diagnosis of coronavirus disease 2019 (COVID-19) relies on clinical features and reverse-transcriptase polymerase chain reaction testing, but the sensitivity is limited. Carotid CTA is a routine acute stroke investigation and includes the lung apices. We evaluated CTA as a potential COVID-19 diagnostic imaging biomarker.

MATERIALS AND METHODS: This was a multicenter, retrospective study (n = 225) including CTAs of patients with suspected acute stroke from 3 hyperacute stroke units (March-April 2020). We evaluated the reliability and accuracy of candidate diagnostic imaging biomarkers. Demographics, clinical features, and risk factors for COVID-19 and stroke were analyzed using univariate and multivariate statistics.

RESULTS: Apical ground-glass opacification was present in 22.2% (50/225) of patients. Ground-glass opacification had high interrater reliability (Fleiss κ = 0.81; 95% CI, 0.68-0.95) and, compared with reverse-transcriptase polymerase chain reaction, had good diagnostic performance (sensitivity, 75% [95% CI, 56-87]; specificity, 81% [95% CI, 71-88]; OR = 11.65 [95% CI, 4.14-32.78]; P < .001) on multivariate analysis. In contrast, all other contemporaneous demographic, clinical, and imaging features available at CTA were not diagnostic for COVID-19. The presence of apical ground-glass opacification was an independent predictor of increased 30-day mortality (18.0% versus 5.7%, P = .017; hazard ratio = 3.51; 95% CI, 1.42-8.66; P = .006).

CONCLUSIONS: We identified a simple, reliable, and accurate COVID-19 diagnostic and prognostic imaging biomarker obtained from CTA lung apices: the presence or absence of ground-glass opacification. Our findings have important implications in the management of patients presenting with suspected stroke through early identification of COVID-19 and the subsequent limitation of disease transmission.

来源:AJNR Am J Neuroradiol,查看原文。版权归原作者所有。

引用

  1. Siddiqui J, Bala F, Sciacca S, et al. COVID-19 Stroke Apical Lung Examination Study: A Diagnostic and Prognostic Imaging Biomarker in Suspected Acute Stroke. AJNR Am J Neuroradiol. 2020. PMID: 32943416. doi:10.3174/ajnr.A6832

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。